Watch the video interview with John S. Ikonomids, M.D., Chief of the Division of Cardothoracic Surgery at MUSC, and Daniel H. Steinberg, M.D., an interventional cardiologist at the MUSC Heart and Vascular Center, discussing transcathether aortic-valve replacement  (TAVR), a minimally invasive alternative to surgical aortic-valve replacement in select patients with severe aortic stenosis. TAVR is already approved for inoperable patients and  has been recommended for approval by an FDA advisory panel in high-risk surgical patients. Drs. Ikonomidis and Steinberg also discuss MUSC's involvement as a site in the PARTNER 2 trial, which will examine the use of a smaller device in intermediate-risk surgical patients.